Intellia Therapeutics Analyst Doubles Price Target: What You Need To Know

An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. NTLA. Here's why. 

The Intellia Analyst: SVB Leerink analyst Mani Foroohar, M.D. reiterated an Outperform rating on Intellia and increased his price target from $81 to $159.

The Intellia Takeaways: Intellia Therapeutics hosted a webcast Monday validating the life sciences company's approach to in vivo gene editing through its therapeutic NTLA-2001, Foroohar said in a note. 

The strength of the interim data from Phase 1 clinical trials and NTLA-2001's safety profile suggests NTLA-2001 will have a high chance at clinical success and positive efficacy, the analyst said.

SVB Leerin's updated financial model for the life sciences company factors in a 70% probability of success (up from 40%) for the use of NTLA-2001 in treating hATTR with polyneuropathy, and a 40% probability of success (up from 35%) for the alpha-1 antitrypsin therapy, ultimately leading to the $159 per share price target.

Click here to read more about the interim data from Phase 1 clinical results.

NTLA Price Action: Intellia shares were up 50.21% at $133.43 at the close Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechPrice TargetReiterationAnalyst RatingsGeneralMani ForooharSVB Leerin
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!